KURA ONCOLOGY, INC. Proceeds from Issuance of Debt
KURA ONCOLOGY, INC. (KURA) reported Proceeds from Issuance of Debt of $5.00 million for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2015-08-14
- KURA ONCOLOGY, INC. proceeds from issuance of debt for the quarter ending 2015-06-30 was $0.00.
- KURA ONCOLOGY, INC. proceeds from issuance of debt for the quarter ending 2015-03-31 was $5.00M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month |
|---|---|---|
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $5.00M 10-Q · filed 2015-08-14 |
| 2015-03-31 | $5.00M 10-Q · filed 2015-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |